Living with vitiligo: so what if our skin looks a little different
By helping reduce post-meal sugar spikes and supporting satiety signaling, this formula may make it easier to feel satisfied, avoid crashes, and stay in better control of appetite throughout the day
Ascorbate recycling in human erythrocytes: role of GSH in reducing dehydroascorbate
Ozempic, Mounjaro, Trulicity, Saxenda, Rybelsus, and Victoza are not included in the Bridge because they are indicated for diabetes (not weight loss)
Effective January 1, 2026, Medi-Cal Rx is excluding coverage for GLP-1 medications prescribed for weight loss: [12] Wegovy, Zepbound, Saxenda: Completely removed from the Contract Drugs List for weight loss Ozempic, Mounjaro, Rybelsus: Restricted to Type 2 diabetes onlyweight loss claims will auto-deny Existing prior authorizations end December 31, 2025 Exceptions: Members under age 21 may still qualify via EPSDT Non-weight-loss indications (Zepbound for OSA, Wegovy for cardiovascular) may still get PA approval This does NOT affect Kaiser commercial or employer-sponsored plansonly Medi-Cal members
One hope is that ePA democratizes access: a small practice with ePA tools can submit PAs just as fast as a large hospital